Related Experiment Video
Updated: Aug 18, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis
Abstract:
The ability to degrade amyloid A fibrils was studied in the serum of 31 patients with amyloidosis associated with rheumatoid arthritis, 33 patients with rheumatoid arthritis without amyloidosis, and 47 healthy controls. Fibrillar amyloid A protein and the radial diffusion method were used. The mean degrading activity in serum was significantly lower in patients with rheumatoid arthritis complicated by amyloidosis (58 +/- 19% SD of the activity in a pooled sample of sera from 100 healthy blood donors used as standard) than in patients with rheumatoid arthritis alone (78 +/- 14%; p less than 0.001) or controls (99 +/- 19%; p less than 0.001). Alpha 1-antitrypsin, concentrations of which were raised in both groups of patients, inhibited the degrading activity in serum even in low concentrations. A negative correlation between degrading activity and alpha 1-antitrypsin concentrations was observed. These findings suggest that reduced amyloid-A-degrading activity is due to inhibition rather than to deficiency of enzyme.
Insights
Serum
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) can lead to amyloidosis.
- Amyloid A (AA) fibril deposition is a hallmark of AA amyloidosis.
- Understanding the degradation of AA fibrils is crucial for disease management.
Purpose of the Study:
- To investigate the serum's capacity to degrade amyloid A fibrils.
- To compare this activity in patients with and without rheumatoid arthritis-associated amyloidosis.
- To identify factors influencing amyloid A fibril degradation.
Main Methods:
- Radial diffusion method was employed.
- Fibrillar amyloid A protein was used as a substrate.
- Serum samples from patients with amyloidosis, RA without amyloidosis, and healthy controls were analyzed.
Main Results:
- Serum amyloid A (AA) fibril degrading activity was significantly lower in patients with RA and amyloidosis compared to RA patients without amyloidosis and healthy controls.
- Elevated alpha 1-antitrypsin concentrations were observed in both patient groups.
- Alpha 1-antitrypsin inhibited AA fibril degrading activity, showing a negative correlation with activity levels.
Conclusions:
- Reduced amyloid A fibril degrading activity in patients with rheumatoid arthritis-associated amyloidosis is attributed to inhibition, not enzyme deficiency.
- Alpha 1-antitrypsin is identified as a key inhibitor of amyloid A fibril degradation in serum.
- These findings suggest potential therapeutic targets for managing amyloidosis.

